Tharimmune to Present at 2024 BIO International Convention [Yahoo! Finance]
Tharimmune, Inc. (THAR)
Company Research
Source: Yahoo! Finance
developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be presenting at the 2024 BIO International Convention being held June 3-6, 2024 in San Diego. The Company will be presenting at the convention and will hold 1x1 meetings with investors and industry leaders. Event: 2024 BIO International Convention Date: Monday, June 3, 2024 Time: 1:45 p.m. Pacific Time Location: Company Presentation Theater 3 To schedule a meeting with the Company's management at the convention, please submit a meeting request through the BIO One-on-One Partnering™ system or contact Tirth Patel from LHA Investor Relations at tpatel@lhai.com About Tharimmune Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The Company's lead clinical-stage asset, TH104 is known to suppress chronic, debilitating pruritus or "uncontrollable itching" in PBC, a rar
Show less
Read more
Impact Snapshot
Event Time:
THAR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
THAR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
THAR alerts
High impacting Tharimmune, Inc. news events
Weekly update
A roundup of the hottest topics
THAR
News
- Tharimmune Announces $2.08 Million Private PlacementAccesswire
- Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary CholangitisAccesswire
- Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis [Yahoo! Finance]Yahoo! Finance
- Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary CholangitisAccesswire
- Tharimmune to Present at 2024 BIO International ConventionAccesswire
THAR
Sec Filings
- 6/20/24 - Form 8-K
- 6/12/24 - Form S-8
- 6/11/24 - Form 8-K
- THAR's page on the SEC website